Title |
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
|
---|---|
Published in |
Cancer Cell, December 2014
|
DOI | 10.1016/j.ccell.2014.11.006 |
Pubmed ID | |
Authors |
Maria Romina Girotti, Filipa Lopes, Natasha Preece, Dan Niculescu-Duvaz, Alfonso Zambon, Lawrence Davies, Steven Whittaker, Grazia Saturno, Amaya Viros, Malin Pedersen, Bart M.J.M. Suijkerbuijk, Delphine Menard, Robert McLeary, Louise Johnson, Laura Fish, Sarah Ejiama, Berta Sanchez-Laorden, Juliane Hohloch, Neil Carragher, Kenneth Macleod, Garry Ashton, Anna A. Marusiak, Alberto Fusi, John Brognard, Margaret Frame, Paul Lorigan, Richard Marais, Caroline Springer |
Abstract |
BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which drive paradoxical reactivation of the pathway. We describe pan-RAF inhibitors (CCT196969, CCT241161) that also inhibit SFKs. These compounds do not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma. They inhibit melanoma cells and patient-derived xenografts that are resistant to BRAF and BRAF/MEK inhibitors. Thus, paradox-breaking pan-RAF inhibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistance. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 8 | 24% |
United States | 7 | 21% |
Spain | 1 | 3% |
Korea, Republic of | 1 | 3% |
Mexico | 1 | 3% |
Costa Rica | 1 | 3% |
France | 1 | 3% |
Unknown | 14 | 41% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 25 | 74% |
Scientists | 6 | 18% |
Science communicators (journalists, bloggers, editors) | 2 | 6% |
Practitioners (doctors, other healthcare professionals) | 1 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 4 | 1% |
United States | 3 | <1% |
Netherlands | 1 | <1% |
France | 1 | <1% |
Sweden | 1 | <1% |
Portugal | 1 | <1% |
South Africa | 1 | <1% |
Germany | 1 | <1% |
Japan | 1 | <1% |
Other | 1 | <1% |
Unknown | 297 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 74 | 24% |
Student > Ph. D. Student | 69 | 22% |
Student > Bachelor | 52 | 17% |
Student > Master | 20 | 6% |
Other | 16 | 5% |
Other | 39 | 13% |
Unknown | 42 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 113 | 36% |
Biochemistry, Genetics and Molecular Biology | 73 | 23% |
Medicine and Dentistry | 35 | 11% |
Chemistry | 17 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 2% |
Other | 16 | 5% |
Unknown | 53 | 17% |